ZimVie: Screening Cheap (Rating Upgrade)

  • ZimVie's stock has plunged over 40% since my downgrade, but recent cost reductions are improving profitability, and the stock is forming a bottoming pattern. Despite continued revenue declines, especially internationally, EBITDA margins have expanded and full-year guidance remains achievable. Valuation is now attractive, with ZIMV trading at a significant discount to dental implant peers on a Fwd EV/EBITDA basis.